Personal tools

MCL coexpression mm9:92: Difference between revisions

From FANTOM5_SSTAR

Jump to: navigation, search
No edit summary
No edit summary
Line 3: Line 3:
|coexpression_dpi_cluster_scores_median=0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.778001303149599,0.482935312308361,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
|coexpression_dpi_cluster_scores_median=0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0.778001303149599,0.482935312308361,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
|gostat_on_MCL_coexpression=GO:0005126;hematopoietin/interferon-class (D200-domain) cytokine receptor binding;1.86034201046507e-05;16156,16191,16163,16198!GO:0005125;cytokine activity;1.86034201046507e-05;16156,16191,16163,16198,14176,56708!GO:0008083;growth factor activity;0.00250463816784521;16156,16191,16198,14176!GO:0005102;receptor binding;0.00326751961204418;16156,16191,16163,16198,14176,56708!GO:0005615;extracellular space;0.025157508354791;16163,12836,16156,16191,68567,14176,16198,56708!GO:0005308;creatine transporter activity;0.025157508354791;102857!GO:0005144;interleukin-13 receptor binding;0.025157508354791;16163!GO:0005140;interleukin-9 receptor binding;0.025157508354791;16198!GO:0005309;creatine:sodium symporter activity;0.025157508354791;102857!GO:0005142;interleukin-11 receptor binding;0.025157508354791;16156!GO:0042225;interleukin-5 biosynthetic process;0.025157508354791;16198!GO:0017047;adrenocorticotropin-releasing hormone binding;0.025157508354791;12919!GO:0045405;regulation of interleukin-5 biosynthetic process;0.025157508354791;16198!GO:0015881;creatine transport;0.025157508354791;102857!GO:0045407;positive regulation of interleukin-5 biosynthetic process;0.025157508354791;16198!GO:0044421;extracellular region part;0.0305231013189292;16163,12836,16156,16191,68567,14176,16198,56708!GO:0005137;interleukin-5 receptor binding;0.0377155873938278;16191!GO:0017046;peptide hormone binding;0.0377155873938278;12919!GO:0032634;interleukin-5 production;0.0377155873938278;16198!GO:0004692;cGMP-dependent protein kinase activity;0.0377155873938278;19092!GO:0051247;positive regulation of protein metabolic process;0.04664591983252;16191,16198!
|gostat_on_MCL_coexpression=GO:0005126;hematopoietin/interferon-class (D200-domain) cytokine receptor binding;1.86034201046507e-05;16156,16191,16163,16198!GO:0005125;cytokine activity;1.86034201046507e-05;16156,16191,16163,16198,14176,56708!GO:0008083;growth factor activity;0.00250463816784521;16156,16191,16198,14176!GO:0005102;receptor binding;0.00326751961204418;16156,16191,16163,16198,14176,56708!GO:0005615;extracellular space;0.025157508354791;16163,12836,16156,16191,68567,14176,16198,56708!GO:0005308;creatine transporter activity;0.025157508354791;102857!GO:0005144;interleukin-13 receptor binding;0.025157508354791;16163!GO:0005140;interleukin-9 receptor binding;0.025157508354791;16198!GO:0005309;creatine:sodium symporter activity;0.025157508354791;102857!GO:0005142;interleukin-11 receptor binding;0.025157508354791;16156!GO:0042225;interleukin-5 biosynthetic process;0.025157508354791;16198!GO:0017047;adrenocorticotropin-releasing hormone binding;0.025157508354791;12919!GO:0045405;regulation of interleukin-5 biosynthetic process;0.025157508354791;16198!GO:0015881;creatine transport;0.025157508354791;102857!GO:0045407;positive regulation of interleukin-5 biosynthetic process;0.025157508354791;16198!GO:0044421;extracellular region part;0.0305231013189292;16163,12836,16156,16191,68567,14176,16198,56708!GO:0005137;interleukin-5 receptor binding;0.0377155873938278;16191!GO:0017046;peptide hormone binding;0.0377155873938278;12919!GO:0032634;interleukin-5 production;0.0377155873938278;16198!GO:0004692;cGMP-dependent protein kinase activity;0.0377155873938278;19092!GO:0051247;positive regulation of protein metabolic process;0.04664591983252;16191,16198!
|ontology_enrichment_celltype=CL:0000217!1.87e-86!2;CL:0000328!1.87e-86!2;CL:0002573!1.87e-86!2;CL:0002376!1.87e-86!2;CL:0000218!1.87e-86!2;CL:0000692!1.87e-86!2;CL:0002377!1.87e-86!2;CL:0002375!1.87e-86!2;CL:0000215!3.28e-58!3;CL:0000630!3.28e-58!3;CL:0000325!6.66e-30!6;CL:0000333!1.57e-18!10;CL:0000095!1.57e-18!10;CL:0000243!1.57e-18!10;CL:0000123!1.57e-18!10;CL:0000125!1.57e-18!10;CL:0000030!1.57e-18!10;CL:0000339!1.57e-18!10
|ontology_enrichment_disease=
|ontology_enrichment_uberon=UBERON:0000010!5.67e-17!11
}}
}}

Revision as of 21:27, 11 October 2012


Phase1 CAGE Peaks

 Short description
Mm9::chr10:109320794..109320838,-p@chr10:109320794..109320838
-
Mm9::chr10:119799722..119799725,-p@chr10:119799722..119799725
-
Mm9::chr10:119807254..119807257,-p@chr10:119807254..119807257
-
Mm9::chr10:17797302..17797310,+p@chr10:17797302..17797310
+
Mm9::chr10:17797357..17797381,+p@chr10:17797357..17797381
+
Mm9::chr10:85649293..85649317,-p@chr10:85649293..85649317
-
Mm9::chr10:88896799..88896836,-p@chr10:88896799..88896836
-
Mm9::chr10:89083964..89083982,-p1@Slc17a8
Mm9::chr11:19939078..19939081,+p@chr11:19939078..19939081
+
Mm9::chr11:35657903..35657922,-p@chr11:35657903..35657922
-
Mm9::chr11:53448200..53448205,-p1@Il13
Mm9::chr11:53534292..53534297,+p1@Il5
Mm9::chr11:70004825..70004828,-p@chr11:70004825..70004828
-
Mm9::chr11:70012374..70012379,+p@chr11:70012374..70012379
+
Mm9::chr11:8345098..8345105,-p@chr11:8345098..8345105
-
Mm9::chr11:95431141..95431161,+p@chr11:95431141..95431161
+
Mm9::chr11:99720036..99720055,-p@chr11:99720036..99720055
-
Mm9::chr11:99720058..99720068,-p@chr11:99720058..99720068
-
Mm9::chr12:109726417..109726425,+p@chr12:109726417..109726425
+
Mm9::chr12:109726441..109726451,+p@chr12:109726441..109726451
+
Mm9::chr12:45626544..45626549,+p@chr12:45626544..45626549
+
Mm9::chr12:45626593..45626609,+p@chr12:45626593..45626609
+
Mm9::chr12:45626625..45626647,+p@chr12:45626625..45626647
+
Mm9::chr12:45626679..45626689,+p@chr12:45626679..45626689
+
Mm9::chr12:45626698..45626717,+p@chr12:45626698..45626717
+
Mm9::chr12:45626725..45626728,+p@chr12:45626725..45626728
+
Mm9::chr12:77883259..77883263,+p@chr12:77883259..77883263
+
Mm9::chr13:13485661..13485690,-p3@Gpr137b
Mm9::chr13:20332675..20332683,+p@chr13:20332675..20332683
+
Mm9::chr13:56583616..56583619,-p1@Il9
Mm9::chr13:5863061..5863072,+p@chr13:5863061..5863072
+
Mm9::chr13:96214718..96214732,-p1@Crhbp
Mm9::chr14:32478998..32479009,+p@chr14:32478998..32479009
+
Mm9::chr14:32542200..32542203,-p@chr14:32542200..32542203
-
Mm9::chr15:7447375..7447379,+p@chr15:7447375..7447379
+
Mm9::chr15:7447493..7447500,+p@chr15:7447493..7447500
+
Mm9::chr15:76032691..76032704,-p@chr15:76032691..76032704
-
Mm9::chr15:80502052..80502063,+p4@Fam83f
Mm9::chr15:80502078..80502107,+p2@Fam83f
Mm9::chr15:80502116..80502126,+p5@Fam83f
Mm9::chr15:87455644..87455660,+p7@Fam19a5
Mm9::chr15:87455675..87455691,+p1@Fam19a5
Mm9::chr15:87482469..87482479,+p@chr15:87482469..87482479
+
Mm9::chr15:87485366..87485375,+p@chr15:87485366..87485375
+
Mm9::chr16:42750876..42750877,+p@chr16:42750876..42750877
+
Mm9::chr17:10914421..10914424,-p@chr17:10914421..10914424
-
Mm9::chr17:11578268..11578275,-p@chr17:11578268..11578275
-
Mm9::chr17:23813529..23813550,-p@chr17:23813529..23813550
-
Mm9::chr17:27698251..27698260,+p@chr17:27698251..27698260
+
Mm9::chr17:27698285..27698292,+p@chr17:27698285..27698292
+
Mm9::chr17:27698297..27698304,+p@chr17:27698297..27698304
+
Mm9::chr17:27698308..27698322,+p@chr17:27698308..27698322
+
Mm9::chr18:24270578..24270588,-p@chr18:24270578..24270588
-
Mm9::chr18:24270590..24270609,-p@chr18:24270590..24270609
-
Mm9::chr18:5404428..5404435,-p@chr18:5404428..5404435
-
Mm9::chr18:5404496..5404500,-p@chr18:5404496..5404500
-
Mm9::chr18:5404573..5404587,-p@chr18:5404573..5404587
-
Mm9::chr18:57302272..57302282,+p16@Megf10
Mm9::chr18:57302324..57302348,+p6@Megf10
Mm9::chr18:57302359..57302364,+p18@Megf10
Mm9::chr18:57302368..57302389,+p7@Megf10
Mm9::chr18:57302392..57302409,+p11@Megf10
Mm9::chr18:57302410..57302419,+p17@Megf10
Mm9::chr18:60878337..60878341,-p@chr18:60878337..60878341
-
Mm9::chr18:60878342..60878360,-p@chr18:60878342..60878360
-
Mm9::chr18:60878370..60878380,-p@chr18:60878370..60878380
-
Mm9::chr19:4214416..4214432,+p1@Clcf1
Mm9::chr19:5447770..5447773,-p@chr19:5447770..5447773
-
Mm9::chr19:59116443..59116460,-p@chr19:59116443..59116460
-
Mm9::chr1:178765650..178765663,+p@chr1:178765650..178765663
+
Mm9::chr1:185424641..185424650,+p@chr1:185424641..185424650
+
Mm9::chr1:58782860..58782907,+p@chr1:58782860..58782907
+
Mm9::chr1:74428217..74428226,+p12@Slc11a1
Mm9::chr2:112219423..112219441,+p2@2410042D21Rik
Mm9::chr2:13480132..13480139,-p@chr2:13480132..13480139
-
Mm9::chr2:13496978..13496987,+p@chr2:13496978..13496987
+
Mm9::chr2:13497144..13497155,+p@chr2:13497144..13497155
+
Mm9::chr2:13497160..13497184,+p@chr2:13497160..13497184
+
Mm9::chr2:148539476..148539483,+p@chr2:148539476..148539483
+
Mm9::chr3:57305683..57305692,-p@chr3:57305683..57305692
-
Mm9::chr3:79740359..79740368,+p@chr3:79740359..79740368
+
Mm9::chr4:135529408..135529431,-p@chr4:135529408..135529431
-
Mm9::chr4:135529437..135529446,-p@chr4:135529437..135529446
-
Mm9::chr5:139954888..139954902,-p4@Zfand2a
Mm9::chr5:28144366..28144367,-p@chr5:28144366..28144367
-
Mm9::chr5:31247969..31247995,-p3@Cgref1
Mm9::chr5:31248027..31248036,-p4@Cgref1
Mm9::chr5:31248044..31248049,-p5@Cgref1
Mm9::chr5:73237669..73237708,-p@chr5:73237669..73237708
-
Mm9::chr5:98683165..98683177,+p3@Fgf5
Mm9::chr5:98683193..98683209,+p4@Fgf5
Mm9::chr5:99395809..99395818,-p11@Prkg2
Mm9::chr6:137465516..137465540,-p@chr6:137465516..137465540
-
Mm9::chr6:137468262..137468263,-p13@Eps8
Mm9::chr6:137468401..137468421,-p3@Eps8
Mm9::chr6:31038213..31038222,-p1@ENSMUST00000123757
Mm9::chr6:31038349..31038357,-p2@ENSMUST00000123757
Mm9::chr6:31038464..31038481,-p@chr6:31038464..31038481
-
Mm9::chr6:31038542..31038552,-p@chr6:31038542..31038552
-
Mm9::chr6:31629332..31629339,+p@chr6:31629332..31629339
+
Mm9::chr6:72331674..72331699,-p@chr6:72331674..72331699
-
Mm9::chr6:72331748..72331753,-p@chr6:72331748..72331753
-
Mm9::chr7:114808192..114808207,+p@chr7:114808192..114808207
+
Mm9::chr7:114866423..114866442,+p@chr7:114866423..114866442
+
Mm9::chr7:137963621..137963654,+p@chr7:137963621..137963654
+
Mm9::chr7:137963832..137963843,+p@chr7:137963832..137963843
+
Mm9::chr7:138004756..138004766,+p@chr7:138004756..138004766
+
Mm9::chr7:138009200..138009202,+p8@Plekha1
Mm9::chr7:138009473..138009484,+p4@Plekha1
Mm9::chr7:138010877..138010906,-p@chr7:138010877..138010906
-
Mm9::chr7:138011022..138011028,+p@chr7:138011022..138011028
+
Mm9::chr7:138011031..138011037,+p@chr7:138011031..138011037
+
Mm9::chr7:138011048..138011054,+p@chr7:138011048..138011054
+
Mm9::chr7:4729743..4729746,-p1@Il11
Mm9::chr8:113317461..113317484,-p@chr8:113317461..113317484
-
Mm9::chr8:113317507..113317514,-p@chr8:113317507..113317514
-
Mm9::chr8:11798720..11798730,+p@chr8:11798720..11798730
+
Mm9::chr8:124754082..124754117,+p@chr8:124754082..124754117
+
Mm9::chr8:74104415..74104425,+p18@Slc27a1
Mm9::chr8:74104427..74104464,+p9@Slc27a1
Mm9::chr9:108884993..108885013,+p4@Col7a1
Mm9::chr9:108885020..108885041,+p3@Col7a1
Mm9::chr9:108885049..108885071,+p5@Col7a1
Mm9::chr9:108886927..108886944,+p@chr9:108886927..108886944
+
Mm9::chr9:14575585..14575594,-p7@1700012B09Rik
Mm9::chr9:24119263..24119266,-p@chr9:24119263..24119266
-
Mm9::chr9:24146097..24146107,+p1@ENSMUST00000098926
Mm9::chr9:24146160..24146163,+p3@ENSMUST00000098926
Mm9::chr9:24172587..24172594,+p@chr9:24172587..24172594
+
Mm9::chr9:32560436..32560445,+p@chr9:32560436..32560445
+
Mm9::chr9:78482024..78482068,+p@chr9:78482024..78482068
+
Mm9::chrX:149092046..149092052,-p@chrX:149092046..149092052
-
Mm9::chrX:70920785..70920788,+p24@Slc6a8
Mm9::chrX:70920839..70920855,+p5@Slc6a8
Mm9::chrX:70920870..70920877,+p21@Slc6a8
Mm9::chrX:70920879..70920886,+p25@Slc6a8
Mm9::chrX:7623717..7623719,+p@chrX:7623717..7623719
+


Enriched pathways on this co-expression cluster<b>Summary:</b><br>Canonical pathway gene sets were compiled from Reactome, Wikipathways and KEGG. For the major signaling pathways, the transcriptionally-regulated genes (downstream targets) were obtained from Netpath. Combined, the canonical pathways and downstream targets totaled 489 human gene sets. The corresponding M. musculus gene sets were inferred by homology using the HomoloGene database. Enrichment for each of the canonical 489 pathways and gene sets included in the co-expression cluster was assessed by the hypergeometric probability. The resulting P values were also then adjusted by the Benjamini-Hochberg method for multiple comparisons.<br><b>Analyst: </b>Emmanuel Dimont<br><br>link to source dataset<br>data

GO IDGO nameFDR corrected p-value
GO:0005126hematopoietin/interferon-class (D200-domain) cytokine receptor binding1.86034201046507e-05
GO:0005125cytokine activity1.86034201046507e-05
GO:0008083growth factor activity0.00250463816784521
GO:0005102receptor binding0.00326751961204418
GO:0005615extracellular space0.025157508354791
GO:0005308creatine transporter activity0.025157508354791
GO:0005144interleukin-13 receptor binding0.025157508354791
GO:0005140interleukin-9 receptor binding0.025157508354791
GO:0005309creatine:sodium symporter activity0.025157508354791
GO:0005142interleukin-11 receptor binding0.025157508354791
GO:0042225interleukin-5 biosynthetic process0.025157508354791
GO:0017047adrenocorticotropin-releasing hormone binding0.025157508354791
GO:0045405regulation of interleukin-5 biosynthetic process0.025157508354791
GO:0015881creatine transport0.025157508354791
GO:0045407positive regulation of interleukin-5 biosynthetic process0.025157508354791
GO:0044421extracellular region part0.0305231013189292
GO:0005137interleukin-5 receptor binding0.0377155873938278
GO:0017046peptide hormone binding0.0377155873938278
GO:0032634interleukin-5 production0.0377155873938278
GO:0004692cGMP-dependent protein kinase activity0.0377155873938278
GO:0051247positive regulation of protein metabolic process0.04664591983252



Relative expression of the co-expression cluster over median <br>Analyst:




Enriched sample ontology terms on this co-expression cluster<b>Summary:</b>To summarize promoter activities (expression profile of a TSS region) across ~1000 samples, we performed enrichment analysis based on FANTOM5 Sample Ontology (FF ontology). The question here is “in which type of samples the promoter is more active”. To answer this question, we compared expressions (TPMs) in the samples associated with a sample ontology term and the rest of the samples by using the Mann-Whitney rank sum test. To summarize ontologies enriched in this co-expression cluster, we ran the same analysis on an averaged expression profile of all promoters that make up. <b>Analyst:</b> Hideya Kawaji <br><br>links to source dataset<br><br>cell_data<br>uberon_data<br><br>

Uber Anatomy
Ontology termp-valuen
peripheral nervous system5.67e-1711


TFBS overrepresentation<b>Summary:</b>The values shown are the p-values for overrepresentation of the motif in this coexpression cluster. So a small p-value means a strong overrepresentation. <b>Analyst:</b> Michiel de Hoon <br><br>link to source data <br> Novel motifs <br>data <br><br> Jaspar motifs <br>data

Novel motifs




JASPAR motifs


Motifs-log10(p-value)

{{{tfbs_overrepresentation_jaspar}}}

Retrieved from "http://f5-webapp4.gsc.riken.jp/resource_browser/index.php?title=MCL_coexpression_mm9:92&oldid=2156746"